Shareholder alert: ademi llp investigates whether intra-cellular therapies, inc. is obtaining a fair price for its public shareholders

Milwaukee--(business wire)--ademi llp is investigating intra-cellular therapies (nasdaq: itci) for possible breaches of fiduciary duty and other violations of law in its transaction with johnson & johnson. click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. there is no cost or obligation to you. in the transaction, intra-cellular therapies stockholders will receive only $132.00 per share in cash.
ITCI Ratings Summary
ITCI Quant Ranking